Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen.

Haq K, Jia Y, Elahi SM, MacLean S, Akache B, Gurnani K, Chattopadhyay A, Nazemi-Moghaddam N, Gilbert R, McCluskie MJ, Weeratna RD.

Vaccine. 2019 Sep 7. pii: S0264-410X(19)31168-5. doi: 10.1016/j.vaccine.2019.08.079. [Epub ahead of print]

2.

Chemical Derivatization Strategy for Extending the Identification of MHC Class I Immunopeptides.

Chen R, Fauteux F, Foote S, Stupak J, Tremblay TL, Gurnani K, Fulton KM, Weeratna RD, Twine SM, Li J.

Anal Chem. 2018 Oct 2;90(19):11409-11416. doi: 10.1021/acs.analchem.8b02420. Epub 2018 Sep 19.

PMID:
30192525
3.

Development of a recombinant murine tumour model using hepatoma cells expressing hepatitis C virus nonstructural antigens.

Young KG, Haq K, MacLean S, Dudani R, Elahi SM, Gilbert R, Weeratna RD, Krishnan L.

J Viral Hepat. 2018 Jun;25(6):649-660. doi: 10.1111/jvh.12856. Epub 2018 Feb 21.

PMID:
29316037
4.

An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma.

Stark FC, Weeratna RD, Deschatelets L, Gurnani K, Dudani R, McCluskie MJ, Krishnan L.

Vaccines (Basel). 2017 Oct 26;5(4). pii: E38. doi: 10.3390/vaccines5040038.

5.

Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates.

Weeratna RD, Chikh G, Zhang L, Fraser JD, Thorn JM, Merson JR, McCluskie MJ, Champion BR, Davis HL.

Immun Inflamm Dis. 2016 Apr 1;4(2):135-147. eCollection 2016 Jun.

6.

In vivo screen of genetically conserved Streptococcus pneumoniae proteins for protective immunogenicity.

Anderson RJ, Guru S, Weeratna R, Makinen S, Falconer DJ, Sheppard NC, Lang S, Chang B, Goenaga AL, Green BA, Merson JR, Gracheck SJ, Eyles JE.

Vaccine. 2016 Dec 7;34(50):6292-6300. doi: 10.1016/j.vaccine.2016.10.061. Epub 2016 Nov 2.

PMID:
27816374
7.

Effects of KLK Peptide on Adjuvanticity of Different ODN Sequences.

Chikh G, Luu R, Patel S, Davis HL, Weeratna RD.

Vaccines (Basel). 2016 May 4;4(2). pii: E14. doi: 10.3390/vaccines4020014.

8.

CpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE).

Makinen SR, Zhu Q, Davis HL, Weeratna RD.

Int Immunol. 2016 Sep;28(9):453-61. doi: 10.1093/intimm/dxw017. Epub 2016 Apr 7.

PMID:
27055469
9.

Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7.

Akache B, Weeratna RD, Deora A, Thorn JM, Champion B, Merson JR, Davis HL, McCluskie MJ.

Vaccines (Basel). 2016 Jan 21;4(1). pii: E3. doi: 10.3390/vaccines4010003.

10.

Current opportunities and challenges in intradermal vaccination.

Chen D, Bowersock T, Weeratna R, Yeoh T.

Ther Deliv. 2015;6(9):1101-8. doi: 10.4155/tde.15.65. Epub 2015 Oct 12. Review.

PMID:
26458019
11.

Nonreplicating vaccines can protect african green monkeys from the memphis 37 strain of respiratory syncytial virus.

Eyles JE, Johnson JE, Megati S, Roopchand V, Cockle PJ, Weeratna R, Makinen S, Brown TP, Lang S, Witko SE, Kotash CS, Li J, West K, Maldonado O, Falconer DJ, Lees C, Smith GJ, White P, Wright P, Loudon PT, Merson JR, Jansen KU, Sidhu MK.

J Infect Dis. 2013 Jul 15;208(2):319-29. doi: 10.1093/infdis/jit169. Epub 2013 Apr 17.

PMID:
23596321
12.

CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses.

McCluskie MJ, Weeratna RD, Evans DM, Makinen S, Drane D, Davis HL.

Biomed Res Int. 2013;2013:636847. doi: 10.1155/2013/636847. Epub 2013 Mar 23.

13.

Negative regulation of the type I interferon signaling pathway by synthetic Toll-like receptor 7 ligands.

Forsbach A, Müller C, Montino C, Kritzler A, Nguyen T, Weeratna R, Jurk M, Vollmer J.

J Interferon Cytokine Res. 2012 Jun;32(6):254-68. doi: 10.1089/jir.2011.0091. Epub 2012 Apr 27.

PMID:
22540943
14.

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.

Kuball J, de Boer K, Wagner E, Wattad M, Antunes E, Weeratna RD, Vicari AP, Lotz C, van Dorp S, Hol S, Greenberg PD, Heit W, Davis HL, Theobald M.

Cancer Immunol Immunother. 2011 Feb;60(2):161-71. doi: 10.1007/s00262-010-0929-7. Epub 2010 Oct 21.

15.

A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties.

Samulowitz U, Weber M, Weeratna R, Uhlmann E, Noll B, Krieg AM, Vollmer J.

Oligonucleotides. 2010 Apr;20(2):93-101. doi: 10.1089/oli.2009.0210.

PMID:
20384481
16.

Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses.

Tluk S, Jurk M, Forsbach A, Weeratna R, Samulowitz U, Krieg AM, Bauer S, Vollmer J.

Int Immunol. 2009 May;21(5):607-19. doi: 10.1093/intimm/dxp030. Epub 2009 Mar 30.

17.

Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse.

Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC, Weeratna RD, Krieg AM.

Cancer Immunol Immunother. 2009 Apr;58(4):615-28. doi: 10.1007/s00262-008-0586-2. Epub 2008 Sep 19.

PMID:
18802696
18.

Comparison of d-g3139 and its enantiomer L-g3139 in melanoma cells demonstrates minimal in vitro but dramatic in vivo chiral dependency.

Lai JC, Brown BD, Voskresenskiy AM, Vonhoff S, Klussman S, Tan W, Colombini M, Weeratna R, Miller P, Benimetskaya L, Stein CA.

Mol Ther. 2007 Feb;15(2):270-8.

19.

Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.

Payette PJ, Ma X, Weeratna RD, McCluskie MJ, Shapiro M, Engle RE, Davis HL, Purcell RH.

Intervirology. 2006;49(3):144-51.

PMID:
16428890
20.

Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848).

McCluskie MJ, Cartier JL, Patrick AJ, Sajic D, Weeratna RD, Rosenthal KL, Davis HL.

Antiviral Res. 2006 Feb;69(2):77-85. Epub 2005 Dec 5.

PMID:
16377001
21.

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

Weeratna RD, Makinen SR, McCluskie MJ, Davis HL.

Vaccine. 2005 Nov 1;23(45):5263-70. Epub 2005 Jul 18.

PMID:
16081189
22.

Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Payette P, Davis HL, Schetter C, Krieg AM.

Immunology. 2004 Oct;113(2):212-23.

23.

Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.

Vollmer J, Weeratna RD, Jurk M, Davis HL, Schetter C, Wüllner M, Wader T, Liu M, Kritzler A, Krieg AM.

J Leukoc Biol. 2004 Sep;76(3):585-93. Epub 2004 Jun 24.

PMID:
15218053
24.

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM.

Eur J Immunol. 2004 Jan;34(1):251-62.

25.

CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice.

Weeratna R, Comanita L, Davis HL.

Immunol Cell Biol. 2003 Feb;81(1):59-62.

PMID:
12534947
26.

Novel adjuvant systems.

McCluskie MJ, Weeratna RD.

Curr Drug Targets Infect Disord. 2001 Nov;1(3):263-71. Review.

PMID:
12455400
27.

Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.

McCluskie MJ, Weeratna RD, Payette PJ, Davis HL.

FEMS Immunol Med Microbiol. 2002 Feb 18;32(3):179-85.

28.

Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters.

Weeratna RD, Wu T, Efler SM, Zhang L, Davis HL.

Gene Ther. 2001 Dec;8(24):1872-8.

29.

CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice.

Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL.

FEMS Immunol Med Microbiol. 2001 Dec;32(1):65-71.

30.

The potential of CpG oligodeoxynucleotides as mucosal adjuvants.

McCluskie MJ, Weeratna RD, Payette PJ, Davis HL.

Crit Rev Immunol. 2001;21(1-3):103-20. Review.

PMID:
11642598
31.

Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanisms.

Payette PJ, Weeratna RD, McCluskie MJ, Davis HL.

Gene Ther. 2001 Sep;8(18):1395-400.

32.

The use of CpG DNA as a mucosal vaccine adjuvant.

McCluskie MJ, Weeratna RD, Payette PJ, Davis HL.

Curr Opin Investig Drugs. 2001 Jan;2(1):35-9. Review.

PMID:
11527008
33.

Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs.

Chen Y, Lenert P, Weeratna R, McCluskie M, Wu T, Davis HL, Krieg AM.

Gene Ther. 2001 Jul;8(13):1024-32.

34.

Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.

McCluskie MJ, Weeratna RD, Clements JD, Davis HL.

Vaccine. 2001 Jun 14;19(27):3759-68.

PMID:
11395211
35.

Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies.

Weeratna RD, Brazolot Millan CL, McCluskie MJ, Siegrist CA, Davis HL.

FEMS Immunol Med Microbiol. 2001 Apr;30(3):241-7.

36.

The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.

McCluskie MJ, Weeratna RD, Davis HL.

Vaccine. 2001 Mar 21;19(17-19):2657-60.

PMID:
11257405
37.

Optimization strategies for DNA vaccines.

Weeratna RD, McCluskie MJ, Comanita L, Wu T, Davis HL.

Intervirology. 2000;43(4-6):218-26.

PMID:
11251377
39.

CpG DNA is an effective oral adjuvant to protein antigens in mice.

McCluskie MJ, Weeratna RD, Krieg AM, Davis HL.

Vaccine. 2000 Nov 22;19(7-8):950-7.

PMID:
11115721
40.

The role of CpG in DNA vaccines.

McCluskie MJ, Weeratna RD, Davis HL.

Springer Semin Immunopathol. 2000;22(1-2):125-32. Review.

PMID:
10944807
41.

CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans.

Davis HL, Suparto II, Weeratna RR, Jumintarto, Iskandriati DD, Chamzah SS, Ma'ruf AA, Nente CC, Pawitri DD, Krieg AM, Heriyanto, Smits W, Sajuthi DD.

Vaccine. 2000 Mar 17;18(18):1920-4.

PMID:
10699341
42.

CpG DNA induces stronger immune responses with less toxicity than other adjuvants.

Weeratna RD, McCluskie MJ, Xu Y, Davis HL.

Vaccine. 2000 Mar 6;18(17):1755-62.

PMID:
10699323
43.

Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.

Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM.

J Immunol. 2000 Feb 1;164(3):1617-24.

44.

Immunostimulatory CpG motifs and DNA vaccines.

Weeratna R, Krieg AM, Davis HL.

Methods Mol Med. 2000;29:169-72. doi: 10.1385/1-59259-688-6:169.

PMID:
21374318
45.

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice.

Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL.

Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15553-8.

46.

Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs.

Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, Davis HL.

Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12631-6.

47.

Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides.

Weeratna R, Brazolot Millan CL, Krieg AM, Davis HL.

Antisense Nucleic Acid Drug Dev. 1998 Aug;8(4):351-6.

PMID:
9743472
48.

CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.

Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM.

J Immunol. 1998 Jan 15;160(2):870-6. Erratum in: J Immunol 1999 Mar 1;162(5):3103. Weeranta R [corrected to Weeratna R].

49.

Human and guinea pig immune responses to Legionella pneumophila protein antigens OmpS and Hsp60.

Weeratna R, Stamler DA, Edelstein PH, Ripley M, Marrie T, Hoskin D, Hoffman PS.

Infect Immun. 1994 Aug;62(8):3454-62.

50.

Legionnaires' disease in cardiac transplant patients: a cell-mediated immune response develops despite cyclosporine therapy.

Weeratna R, Marrie TJ, Logan SM, Hoskin D, Hoffman PS, Yates L, Burbridge S, Haldane D, Bezanson G.

J Infect Dis. 1993 Aug;168(2):521-2. No abstract available.

PMID:
8336002

Supplemental Content

Loading ...
Support Center